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SUPPLEMENTARY MATERIALS AND METHODS 
 
 
Cloning of C2c2 locus and screening libraries for MS2 activity Screen 
Genomic DNA from Leptotrichia shahii DSM 19757 (ATCC, Manassas, VA) was extracted 
using the Blood & Cell Culture DNA Mini Kit (Qiagen, Hilden, Germany) and the C2c2 
CRISPR locus was PCR amplified and cloned into a pACYC184 backbone with 
chloramphenicol resistance. For retargeting of the locus to MS2 phage or endogenous targets, the 
wild type spacers in the array were removed and replaced with a Eco31I landing site an 
additional spacer and a degenerate repeat, compatible with Golden Gate cloning. 
 
A custom library consisting of all possible spacers targeting the genome of the bacteriophage 
MS2, excluding spacers containing the Eco31I restriction site, was synthesized by Twist 
Biosciences (San Francisco, CA), cloned into the retargeting backbone with Golden Gate 
cloning, transformed into Endura Duo electrocompetent cells (Lucigen, Middleton, WI) and 
subsequently purified using a NucleoBond Xtra MaxiPrep EF (Machery-Nagel, Düren, 
Germany). 
 
Cloning of libraries and screening for β–lactamase and transcribed/non-transcribed PFS 
screens 
Plasmid libraries for PFS screens were cloned from synthesized oligonucleotides (IDT, 
Coralville, IA) consisting of either 6 or 7 randomized nucleotides downstream of the spacer 1 
target (completed plasmids in Table S5). To generate dsDNA fragments for cloning, these 
ssDNA oligonucleotides were annealed to a short primer for second strand synthesis by large 
Klenow fragment (New England Biolabs, Ipswich, MA). dsDNA fragments were Gibson cloned 
(New England Biolabs) into digested pUC19 at the 5’-region of β–lactamase, downstream of the 
lac promoter, or in a non-transcribed region of pUC19 and electroporated into Endura Duo 
electrocompetent cells (Lucigen). More than 5*106 cells were collected, pooled, and harvested 
for plasmid DNA using a NucleoBond Xtra MaxiPrep EF (Machery-Nagel, Düren, Germany). 
To screen libraries, we co-transformed 50 ng of the pooled library and an equimolar amount of 
the LshC2c2 locus plasmid or pACYC184 plasmid control into E. coli cells (NovaBlue 
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GigaSingles, EMD Millipore, Darmstadt, Germany). After transformation, cells were plated on 
ampicillin and chloramphenicol to select for both plasmids. After 16 hours of growth, >1*106 
cells were harvested for plasmid DNA using a NucleoBond Xtra MaxiPrep EF (Machery-Nagel) 
The target PFS region was PCR amplified and sequenced using a MiSeq (Illumina, San Diego, 
CA) with a single-end 150 cycle kit.  
 
Bacterial phage interference PFS screen assay 
For the phage screen, 50ng of the plasmid library were transformed into NovaBlue(DE3) 
Competent Cells (EMD Millipore) followed by an outgrowth at 37°C for 30 minutes. Three 
different replicates of cells were then grown in Luria broth (LB, Miller’s modification, 10g/L 
tryptone, 5g/L yeast extract, 5g/L NaCl, Sigma, St. Louis, MO) supplemented with 25 µg/mL 
chloramphenicol (Sigma) in a volume of 3.0mL for 30 minutes. Phage conditions were treated 
with 7*109 (10-1 dilution), 7*107 (10-3 dilution), or 7*105 (10-5 dilution) PFU of Bacteriophage 
MS2 (ATCC). After 3 hours of shaking incubation at 37°C, samples were plated on LB-agar 
plates supplemented with chloramphenicol and harvested after 16 hours. DNA was extracted 
using NucleoBond Xtra MaxiPrep EF (Machery-Nagel), PCR amplified around the guide region, 
and sequenced using a MiSeq (Illumina) with a paired-end 150 cycle kit.  
 
Bacterial phage interference assay for individual spacers 
To test individual spacers for MS2 interference, the oligonucleotides encoding the spacer 
sequences (Table S4) flanked by Eco31I sites were ordered from IDT as complementary strands. 
The oligonucleotides (final concentration 10µM) were annealed in 10X T4 ligase buffer (New 
England Biolabs; final concentration 1X) supplemented with 5 units of T4 PNK (New England 
Biolabs). The oligonucleotides were phosphorylated by setting the thermocycler to 37°C for 30 
minutes and then subsequently annealed by heating to 95°C for 5 minutes followed by a -
5°C/minute ramp down to 25°C. Annealed oligos were then cloned into the locus backbone with 
Golden Gate cloning. Plasmids were transformed into C3000 strain E. coli, and the cultures were 
made competent with the Mix and Go kit (Zymo Research, Irvine, CA). C3000 cells were seeded 
from an overnight culture grown to OD600 of 2, at which point they were diluted 1:13 in Top 
Agar (10g/L tryptone, 5g/L yeast extract, 10g/L NaCl, 7g/L agar) and poured on LB-
chloramphenicol plates. Dilutions of MS2 phage in phosphate buffered saline were then spotted 
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on the plates using a multichannel pipette, and plaque formation was recorded after overnight 
incubation. 
 
RFP targeting assay 
An ampicillin resistant RFP-expressing plasmid (pRFP) was transformed into DH5-alpha cells 
(New England Biolabs). Cells containing pRFP were then made chemically competent (Mix and 
Go, Zymo Research) to be used for downstream targeting experiments with pLshC2c2. Spacers 
targeting RFP mRNA were cloned into pLshC2c2 (as described above) and these plasmids were 
transformed into the chemically competent DH5-alpha pRFP cells. Cells were then grown 
overnight under double selection in LB and subjected to analysis by flow cytometry when they 
reached an OD600 of 4.0. Knockdown efficiency was quantified as the percent of RFP positive 
cells compared to a non-targeting spacer control (the endogenous LshC2c2 locus in pACYC184).  
 
To interrogate the effect of LshC2c2 activity on the growth of the host cells, we created a TetR-
inducible version of the RFP plasmid in pBR322 (pBR322_RFP). We transformed E. coli cells 
with this vector and then made them chemically competent (Mix and Go, Zymo Research) to 
prepare them for downstream experiments. We cloned pLshC2c2 plasmids with various spacers 
targeting RFP mRNA as well as their reverse complement controls and transformed them into E. 
coli cells carrying pBR322_RFP and streaked them on double-selection plates to maintain both 
plasmids. Colonies were then picked and grown overnight in LB with double selection. Bacteria 
were diluted to an OD600 of 0.1 and grown at 37C for 1 hour with chloramphenicol selection 
only. RFP expression was then induced using dilutions of anhydrotetracycline (Sigma) and OD600 
measurements were taken every 6 minutes under continuous shaking in a Synergy 2 microplate 
reader (BioTek, Winooski, VT).  
 
C2c2 protein purification  
The mammalian codon-optimized gene for C2c2 (Leptotrichia shahii) was synthesized 
(GenScript, Jiangsu, China) and inserted into a bacterial expression vector (6-His-MBP-TEV, a 
pET based vector generously provided by Doug Daniels) using Golden Gate cloning. The 
LshC2c2 expression construct was transformed into One Shot® BL21(DE3)pLysE (Invitrogen, 
Carlsbad, CA) cells. 10mL of overnight culture were inoculated into 12 liters of Terrific Broth 
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growth media (12g/L tryptone, 24g/L yeast extract, 9.4g/L K2HPO, 2.2g/L KH2PO4, Sigma) 
supplemented with 100 μg/mL.  Cells were then grown at 37 °C to a cell density of 0.2 OD600, at 
which point the temperature was lowered to 21°C. At a cell density of 0.6 OD600, MBP-LshC2c2 
expression was induced by supplementing with IPTG to a final concentration of 500 μM. 
Induced culture was grown for 14-18 hours before harvesting cell paste, which was stored at -
80°C until subsequent purification. 
 
Frozen cell paste was crushed and resuspended via stirring at 4°C in 1L of Lysis Buffer (50 mM 
Hepes pH 7, 2M NaCl, 5 mM MgCl2, 20 mM imidazole) supplemented with protease inhibitors 
(cOmplete, EDTA-free, Roche Diagnostics Corporation, Indianapolis, IN). The resuspended cell 
paste was lysed by lysozyme (Sigma) addition and sonication (Sonifier 450, Branson, Danbury, 
CT). Lysate was cleared by centrifugation at 10,000g for 1 hour, and the supernatant was filtered 
through Stericup 0.45 micron filters (EMD Millipore). Filtered lysate was incubated with Ni-
NTA superflow nickel resin (Qiagen) at 4°C for 1 hour with gentle agitation, and then applied to 
an Econo-column chromatography column (Bio-Rad Laboratories, Hercules, CA). Resin was 
washed with lysis Buffer and eluted with a gradient of imidazole. Fractions containing protein of 
the expected size for MBP-LshC2c2 were pooled and buffer exchanged into TEV Buffer (500 
mM NaCl, 50 mM Hepes pH 7, 5 mM MgCl, 2 mM DTT) with Ultra-15 Centrifugal Filter Unit 
with 50 KDa cutoff (Amicon, EMD Millipore). TEV protease (Sigma) was added and incubated 
at 4°C overnight. After incubation, TEV cleavage was confirmed by SDS-PAGE and Coomassie 
staining, and the sample was concentrated via Centrifugal Filter Unit to 1 mL. Concentrated 
sample was loaded a gel filtration column (HiLoad 16/600 Superdex 200, GE Healthcare Life 
Sciences, Chalfont Saint Giles, United Kingdom) via FPLC (AKTA Pure, GE	Healthcare	Life	Sciences).  The resulting fractions from gel filtration were tested for presence of LshC2c2 
protein by SDS-PAGE; fractions containing LshC2c2 were pooled, buffer exchanged into 
Storage Buffer (1 M NaCl, 50 mM Tris-HCl pH 7.5, 5% glycerol, 2 mM DTT), concentrated, 
and either used directly for biochemical assays or frozen at -80°C for storage.  To calculate the 
approximate size of recombinant LshC2c2, gel filtration standards were run on the same gel 
filtration column equilibrated in 2M NaCl, Hepes pH 7.0. 
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C2c2 HEPN mutant protein purification 
Alanine mutants at each of the four HEPN catalytic residues were generated by Gibson cloning 
and transformed into One Shot® BL21(DE3)pLysE cells (Invitrogen). For each mutant, 6 L of 
Terrific Broth were used to generate cell paste. Protein purification was performed similarly to 
wild type C2c2 with exception of buffer composition being altered to increase stability of 
recombinant protein in solution. Detergent or glycerol was added to Lysis Buffer (50 mM Hepes 
pH 7, 1M NaCl, 5 mM MgCl2, 20 mM imidazole, 1% Triton X-100), Imidazole Elution Buffer 
Buffer (50 mM Hepes pH 7, 1M NaCl, 5 mM MgCl2, 200 mM imidazole, 0.01% Triton X-100, 
10% glycerol) and TEV Buffer (500 mM NaCl, 50 mM Hepes pH 7, 5 mM MgCl, 1 mM DTT, 
0.01% Triton X-100, 10% glycerol). In all situations where HEPN mutants were used 
biochemical analysis, wild type protein used for comparison was purified in the same manner. 
 
Nucleic acid target preparation 
DNA oligo templates for T7 transcription were ordered from IDT (Tables S2, S3). Templates for 
crRNAs were annealed to a short T7 primer (final concentrations 10µM) and incubated with T7 
polymerase overnight at 37°C using the HiScribe T7 Quick High Yield RNA Synthesis kit (New 
England Biolabs). Target templates were PCR amplified to yield dsDNA and then incubated with 
T7 polymerase at 30°C overnight using the same kit.  
 
5’ end labeling was accomplished using the 5’ oligonucleotide kit (VectorLabs, Burlingame, CA) 
and with a maleimide-IR800 probe (LI-COR Biosciences, Lincoln, NE). 3’ end labeling was 
performed using a 3’ oligonucleotide labeling kit (Sigma) using ddUTP-Cy5. Labeled probes 
were purified using Clean and Concentrator columns (Zymo Research).  
 
dsRNA substrates were prepared by mixing 5’-end-labeled ssRNA targets with two-fold excess 
of non-labeled complementary ssRNA oligos in annealing buffer (30mM HEPES pH 7.4, 100 
mM potassium acetate, and 2mM magnesium acetate). Annealing was performed by incubating 
the mixture for 1 minute at 95°C followed by a -1°C/minute ramp down to 23°C.  
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Nuclease Assay 
Nuclease assays were performed with 160nM of end-labeled ssRNA target, 200nM purified 
LshC2c2, and 100nM crRNA, unless otherwise indicated, in nuclease assay buffer (40mM Tris-
HCl, 60mM NaCl, 6mM MgCl2, pH 7.3). Reactions were allowed to proceed for 1 hour at 37°C 
(unless otherwise indicated) and were then quenched with proteinase buffer (proteinase K, 
60mM EDTA, and 4M Urea) for 15 minutes at 37°C. The reactions were then denatured with 
4.5M urea denaturing buffer at 95°C for 5 minutes. Samples were analyzed by denaturing gel 
electrophoresis on 10% PAGE TBE-Urea (Invitrogen) run at 45°C. Gels were imaged using an 
Odyssey scanner (LI-COR Biosciences).  
 
Electrophoretic mobility shift assay 
Target ssRNA binding experiments were performed with a series of half-log complex dilutions 
(crRNA and LshC2c2) from 2μM to 0.2pM (or 1μM to 0.1pM in the case of R1278A LshC2c2). 
Binding assays were performed in nuclease assay buffer supplemented with 10mM EDTA to 
prevent cutting, 5% glycerol, and 10μg/mL heparin in order to avoid non-specific interactions of 
the complex with target RNA. Reactions were incubated at 37°C for 20 minutes and then 
resolved on 6% PAGE TBE gels (Invitrogen) at 4°C (using 0.5X TBE buffer). Gels were imaged 
using an Odyssey scanner (LI-COR Biosciences).  
 
Next-generation sequencing of in vitro cleaved RNA 
In vitro nuclease assays were performed as described above using unlabeled ssRNA targets. 
After one hour, samples were quenched with proteinase K + EDTA and then column purified 
(Clean and Concentrator, Zymo Research). The RNA samples were PNK treated in absence and 
presence of ATP to allow for the enrichment of 3’-P and 5’-OH ends, respectively. The samples 
were then polyphosphatase treated (Epicentre, Madison, WI) before being prepared for next-
generation sequencing using the NEBNext Small RNA Library Prep Set for Illumina sequencing 
(New England Biolabs) with the PCR extension step increased to allow for longer templates to 
be included in the library. Libraries were sequenced on an MiSeq (Illumina) to sufficient depth 
and analyzed using the alignment tool BWA (53). Paired-end alignments were used to extract 
entire transcript sequences using Galaxy tools (https://usegalaxy.org/), and these sequences were 
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analyzed using Geneious 8.1.5 (Biomatters, Auckland, New Zealand) and custom scripts 
(github.com/fengzhanglab). 
 
In vitro co-transcriptional DNA cleavage assay 
The E. coli RNAP co-transcriptional DNA cleavage assay was performed essentially as 
described previously (22). Briefly, 0.8pmol of ssDNA template strand were annealed with 
1.6pmol of RNA in transcription buffer (from E. coli RNAP core enzyme, New England 
Biolabs) without magnesium to prevent RNA hydrolysis. 0.75ul of E. coli RNAP core enzyme 
and Magnesium were added and the reaction incubated at 25°C for 30min and then transferred to 
37°C. 1pmol of freshly denatured nontemplate strand (NTS) were added and incubated at 37°C 
for 15min to obtain elongation complexes (ECs). 4pmol of LshC2C2-crRNA complexes along 
with 1.25 mM of RNTPs were added to the ECs and transcription was allowed to proceed for 1h 
at 37°C. DNA was resolved by denaturing gel electrophoresis on a 10% PAGE TBE-Urea 
(Invitrogen) gels following RNase and proteinase K treatment. 
 
Computational analysis of in vivo PFS screens 
To determine enriched spacers in the bacterial phage interference screens, spacer regions were 
extracted, counted, and normalized to total reads for each sample. For a given spacer, enrichment 
was measured as the log2 ratio compared to the no phage conditions, with a 1.0 psuedocount 
adjustment. 5’ and 3’ PFS regions from spacers above a 1.25 log2 enrichment threshold that 
occurred in all three biological replicates were used to generate sequence logos for the phage 
dilution samples (54). Correlations between replicate conditions were measured using a 
Kendall’s Tau rank correlation and the information coefficient, a mutual information based 
metric for ascertaining similarity (43, 55).  
 
For the β-lactamase PFS screen and transcribed/non-transcribed pUC19 PFS screens, PFS 
regions were extracted, computationally collapsed to 5nt to increase coverage, counted, and 
normalized to total reads for each sample. For a given PFS, enrichment was measured as the log 
ratio compared to pACYC184 control, with a 0.01 psuedocount adjustment. PFSs above a 6 
depletion threshold (β-lactamase screen), a 0.35 depletion threshold (transcribed pUC19 screen), 
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or a 0.5 depletion threshold (non-transcribed pUC19 screen) that occurred in both biological 
replicates were collected and used to generate sequence logos (54). 
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SUPPLEMENTARY FIGURES 
 
 
Figure S1 
 
 
 
Fig. S1: RNA-sequencing of the Leptotrichia shahii locus heterologously expressed in E. coli 
and spacer analysis. Adapted from (19). 
Heterologous expression of the LshC2c2 locus reveals processing of the array. Insert: In silico 
co-folding analysis of a mature direct repeat.  
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Figure S2 
 
 
Fig. S2: MS2 phage screen replicates show agreement and do not have a 5’ PFS 
(A) Rank correlation (Kendall) of normalized crRNA count distributions between replicate 
conditions in the screen. (B) Information coefficient representing the mutual information 
between the normalized crRNA count distributions of replicate conditions in the screen. This 
metric highlights how similar the 10-1 and 10-3 dilution conditions are and how little information 
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is shared between 10-1/10-3 and 10-5/no phage groups. A higher information coefficient represents 
strong correlation and is computed as previously described (43, 55). (C) Box plot showing the 
distribution of normalized crRNA frequencies for the phage-treated conditions (10-1, 10-3, and 10-
5 dilutions) and control screen (no phage) biological replicates (n = 3). The box extends from the 
first to third quartile with whiskers denoting 1.5 times the interquartile range. The mean is 
indicated by the red horizontal bar. The 10-1 and 10-3 phage dilution distributions are significantly 
different than each of the control replicates (****, p < 0.0001). (C) Box plot showing the 
distribution of normalized crRNA frequencies (normalized to no phage condition) for targeting 
and non-targeting guides from the 10-3 diluted phage conditions (n=3). (D) (E) Sequence logo of 
5’ sequences from enriched spacers in each of the phage dilutions. (F) Sequence logos of 3’ 
sequences from enriched spacers in the 10-1 and 10-3 phage dilutions show a PFS. (G) The 
number of targeting and non-targeting control spacers that are consistently enriched (the exact 
number is above each bar). A spacer is considered enriched only if it has a log2 normalized 
crRNA fold change > 1.25 in all three replicates. Within the consistently enriched crRNAs, there 
are 84 sequences that are shared between the 10-1 and 10-3 conditions.  
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Figure S3 
 
 
Fig. S3: MS2 phage screen spacer representation across each PFS. 
(A) Box plot showing the distribution of spacer frequencies with spacers grouped by their 3’ PFS 
for 10-3 phage treated conditions. Box extends from the first to third quartile with the whiskers 
denoting 1.5 times the interquartile range. ****, p < 0.0001. (B) Multiple comparison test 
(ANOVA with Tukey correction) between all possible PFS pairs for the 10-3 phage treated spacer 
distributions. Plotted are the 95% confidence intervals for difference in means between the 
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compared PFS pairs. (C) Box plot showing the distribution of spacer frequencies with spacers 
grouped by their 3’ PFS for non-phage treated conditions. Box extends from the first to third 
quartile with the whiskers denoting 1.5 times the interquartile range. (D) Multiple comparison 
test (ANOVA with Tukey correction) between all possible PFS pairs for the non-phage treated 
spacer distributions. Plotted are the 95% confidence intervals for difference in means between 
the compared PFS pairs. (E) Cumulative frequency plots for the log2 normalized spacer counts. 
Spacers are separated by respective PFS to show the enrichment differences between the 10-3 
phage and control PFS distributions. (F) The enriched spacers from the 10-3 dilution condition 
are plotted according to their position along the MS2 genome. The corresponding gene positions 
are mapped below. (G) Frequency distributions of the non-redundant nearest-neighbor pairwise-
distances between all 150 enriched guides in the 10-3 phage dilution condition (blue) and in a 
bootstrapped simulation of 150 randomly chosen guides (n=10,000) (red). A significant 
difference between both distributions is observed using a two-sample Kolmogorov-Smirnov 
statistic (****, p < 0.0001). Inset: the cumulative frequency distributions for the non-redundant 
nearest-neighbor pairwise-distance distributions for the 10-3 phage dilution condition (blue) and 
bootstrapped simulation (red).  
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Figure S4 
 
Fig. S4: Top hits from MS2 phage screen show interference in plaque assay 
(A) Images from validation of MS2 screen by plaque assay showing reduced plaque formation in 
top hits. Phage dilutions were spotted on bacteria plates at decreasing numbers of plaque forming 
units (PFU). Spacer targets are shown above images; biological replicates are labeled BR1, BR2, 
or BR3. Non-targeting control is the native LshC2c2 locus. (B) Quantitation of MS2 plaque 
assay demonstrating interference by top hits. Interference was quantified by highest dilution 
without plaques. Bars plotted are the mean ± s.e.m. 
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Figure S5 
 
Fig. S5: MS2 plaque assay validates the 3’ H PFS. 
Four spacers for each possible 3’ PFS (A, G, C, and U) are cloned into the pLshC2c2 vector and 
tested for MS2 phage restriction in a plaque forming assay. The images show significantly 
reduced plaque formation for A, C, and U PFSs, and less restriction for the G PFS. Phage 
dilutions were spotted on bacteria plates at decreasing numbers of plaque forming units (PFU). 
Spacer targets are shown above images; three biological replicates are vertically stacked under 
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each protospacer sequence. Non-targeting controls are the native LshC2c2 locus and the 
pACYC184 backbone. 
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Figure S6 
 
Fig. S6. A PFS screen in the β-lactamase mRNA reveals a 3’ H PFS 
(A) Comparison of the normalized crRNA count distributions for the pACYC control and 
LshC2c2 replicates (n=2). Box plots are shown with boxes extending from the first quartile to 
third quartile and whiskers denoting 1.5 times the interquartile range. Significant enrichment and 
depletion is observed in the LshC2c2 replicates (****, p < 0.0001). (B) A 3’ PFS is observed 
from the depleted PFSs (-log2 normalized PFS count fold change >6.0).  
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Figure S7 
 
Fig. S7: Protein purification of LshC2c2. 
(A) Coomassie blue stained acrylamide gel of purified LshC2c2 stepwise purification. A strong 
band just above 150 kD is consistent with the size of LshC2c2 (171 kD). (B) Size exclusion gel 
filtration of LshC2c2. LshC2c2 eluted at a size approximately >160 kD (62.9 mL). (C) Protein 
standards used to calibrate the Superdex 200 column. BDex = Blue Dextran (void volume), Ald 
= Aldolase (158 kD), Ov = Ovalbumin (44 kD), RibA = Ribonuclease A (13.7 kD), Apr = 
Aprotinin (6.5 kD). (D) Calibration curve of the Superdex 200 column.  Kav is calculated as 
(elution volume – void volume)/(geometric column volume – void volume). Standards were 
plotted and fit to a logarithmic curve.  
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Figure S8 
 
 
Fig. S8: Further in vitro characterization of the RNA cleavage kinetics of LshC2c2.  
(A) Denutaring gel of a time series of LshC2c2 ssRNA cleavage using a 5’- and 3-end-labeled 
target 1. (B) A denaturing gel after 1 hour of RNA-cleavage of 5’- and 3-end-labeled target 1 
using LshC2c2-crRNA complex that is serially diluted in half-log steps. Reported band lengths 
are matched from RNA sequencing. 
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Figure S9 
 
 
 
Fig. S9: Characterization of the metal dependence of LshC2c2 RNA cleavage.  
A variety of divalent metal cations are supplemented for the LshC2c2 cleavage reaction using 5’-
end-labeled target 1 incubated for 1 hour. Significant cleavage is only observed for Mg+2. Weak 
cleavage is observed for Ca+2 and Mn+2. Reported band lengths are matched from RNA 
sequencing. 
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Figure S10 
 
Fig. S10: LshC2c2 has no observable cleavage activity when using dsRNA, dsDNA, or 
ssDNA substrates.  
(A) A schematic of the partial dsRNA target. 5’-end-labeled target 1 is annealed to two shorter 
RNAs that are complementary to the regions flanking the protospacer site. This partial dsRNA is 
a more stringent test for dsRNA cutting since it should still allow for LshC2c2 complex binding 
to ssRNA. (B) LshC2c2 cleavage activity after 1 hour of incubation with a dsRNA target shown 
in (A) compared to the ssRNA target 1. No cleavage is observed when using the dsRNA 
substrate. Reported band lengths are matched from RNA sequencing. (C) LshC2c2 cleavage of a 
dsDNA plasmid library incubated for 1 hour. A plasmid library was generated to have seven 
randomized nucleotides 5’ of protospacer 14 to account for any sequence requirements for 
dsDNA cleavage. No cleavage is observed for this dsDNA library. (D) A ssDNA version of 
target 1 is tested for cleavage by LshC2c2 after 1 hour of incubation. No cleavage is observed.   
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Figure S11 
 
Fig. S11: LshC2c2 has no observable cleavage activity on dsDNA targets in a co-
transcriptional cleavage assay 
(A) Schematic of co-transcriptional cleavage assay. C2c2 was incubated with E. coli RNA 
polymerase (RNAP) elongation complexes and rNTP as previously described (22). (B) LshC2c2 
cleavage of DNA target after co-transcriptional cleavage assay. No cleavage is observed. 
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Figure S12 
 
 
Fig. S12: Figure 4. LshC2c2 prefers cleavage at uracil residues.  
(A,C) The cleavage sites of non-homopolymer ssRNA targets 4 (A), and 5 (C) were mapped 
with RNA-sequencing of the cleavage products. The frequency of cleavage at each base is 
colored according to the z-score and shown on the predicted crRNA-ssRNA co-fold secondary 
structure. Fragments used to generate the frequency analysis contained the complete 5’ end. The 
	 25 
5’ and 3’ end of the ssRNA target are indicated by blue and red outlines, on the ssRNA and 
secondary structure, respectively. The 5’ and 3’ end of the spacer (outlined in yellow) is 
indicated by the blue and orange residues highlighted respectively. (B,D) Plot of the frequencies 
of cleavage sites for each position of ssRNA targets 4 and 5 for all reads that begin at the 5’ end. 
The protospacer is indicated by the blue highlighted region. (E) Schematic of homopolymer 
ssRNA targets. The protospacer is indicated by the light blue bar. Homopolymer stretches of A 
(green) and U (red) bases are interspaced by individual bases of G (orange) and C (purple). (F) 
Denaturing gel showing C2c2-crRNA-mediated cleavage patterns of each homopolymer after 3 
hours of incubation. (G) Schematic of ssRNA 4 modified with a hompolymer stretch in the 
highlighted loop (red) for each of the four possible nucleotides (left). Denaturing gel showing 
C2c2-crRNA-mediated cleavage for each of the four possible homopolymer targets after 3 hours 
of incubation. Reported band lengths are matched from RNA sequencing. 
 
  
	 26 
 
Figure S13 
 
Fig. S13: MS2 restriction assay reveals that single HEPN mutants abrogate LshC2c2 
activity.  
All four possible single HEPN mutants were generated in the pLshC2c2 vector (R597A, H602A, 
R1278A, and H1283A) with protospacer 1. Images from plaque assay testing these HEPN 
mutant loci show similar plaque formation to the non-targeting locus and is significantly higher 
than the WtC2c2 locus. Phage dilutions were spotted on bacteria plates at decreasing numbers of 
plaque forming units (PFU). Spacer targets are shown above images; biological replicates are 
labeled BR1, BR2, or BR3. Non-targeting control is the native LshC2c2 locus. 
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Figure S14 
 
 
Fig.  S14: Quantitation of LshC2c2 binding 
(A) Calculation of binding affinity for wildtype LshC2c2-crRNA complex and on-target ssRNA. 
Fraction of protein bound was quantified by densitometry from Fig. 4D and KD was calculated by 
fitting to binding isotherm. (B) Calculation of binding affinity for HEPN mutant R1278A 
LshC2c2-crRNA complex and on-target ssRNA. Fraction of protein bound was quantified by 
densitometry from Fig. 4E and KD was calculated by fitting to binding isotherm. (C) 
Electrophoretic mobility shift assay with HEPN mutant R1278A LshC2c2 against on-target 
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ssRNA in the absence of crRNA. EDTA is supplemented to reaction condition. (D) 
Electrophoretic mobility shift assay crRNA against on-target ssRNA. EDTA is supplemented to 
reaction condition. (E) Calculation of binding affinity for HEPN mutant R1278A LshC2c2 and 
on-target ssRNA in the absence of crRNA. Fraction of protein bound was quantified by 
densitometry from Fig. S12C and KD was calculated by fitting to binding isotherm. (F) 
Calculation of binding affinity for crRNA and on-target ssRNA. Fraction of crRNA bound was 
quantified by densitometry from Fig. S12D and KD was calculated by fitting to binding isotherm. 
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Figure S15 
 
Fig. S15. LshC2c2-crRNA complex has little binding affinity for ssDNA targets.  
Electrophoretic mobility shift assay with HEPN mutant R1278A LshC2c2 against on-target 
ssDNA and non-complementary ssDNA (reverse complement). EDTA is supplemented to 
reaction condition. 
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Figure S16 
 
Fig. S16. Spacer and direct repeat lengths affect the RNA-guided RNase activity of 
LshC2c2. 
(A) Denaturing gel showing crRNA-guided cleavage of ssRNA 1 as a function of spacer length 
after 3 hours of incubation. Reported band lengths are matched from RNA sequencing. (B) 
Denaturing gel showing crRNA-guided cleavage of ssRNA 1 as a function of the direct repeat 
length after 3 hours of incubation. Reported band lengths are matched from RNA sequencing. 
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Figure S17 
 
Fig. S17. RNA-guided RNase activity of LshC2c2 is dependent on direct repeat structure 
and sequence. 
(A) Schematic showing modifications to the crRNA direct repeat stem (top). Altered bases are 
shown in red. Denaturing gel showing crRNA-guided cleavage of ssRNA 1 by each modified 
crRNA after 3 hours of incubation (bottom). Reported band lengths are matched from RNA 
sequencing. (B) Schematic showing modifications to the loop region of the crRNA direct repeat 
(top). Altered bases are shown in red and deletion lengths are indicated by arrows. Denaturing 
gel showing crRNA-guided cleavage of ssRNA 1 by each modified crRNA after 3 hours of 
incubation (bottom). Reported band lengths are matched from RNA sequencing. 	 	
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Figure S18 
 
Fig. S18. The effect of 3’ modifications to the crRNA DR.  
Schematic shows the modifications made to the 3’ end of the DR: single mutations (top-left) or 
deletions (top-right). Altered bases are shown in red and deletion lengths are indicated by 
arrows.  Denaturing gel depicting LshC2c2 cleavage activity by each modified crRNA after 3 
hours of incubation (bottom). Reported band lengths are matched from RNA sequencing. 	 	
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Figure S19 
 
Fig. S19.  Effect of RNA target-crRNA mismatches on LshC2c2 RNase activity. 
(A) Quantification of MS2 plaque assays testing single mismatches at various positions in the 
spacer. Single mismatches have minimal effect on phage interference. Locations and identity of 
mismatches are shown in red. . (n=3 biological replicates. **, p < 0.01 ; ***, p < 0.001 compared 
to pACYC184 by t-test. Bars represent mean ± s.e.m). (B) Quantification of MS2 plaque assays 
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testing double mismatches at various positions in the spacer. Consecutive double mismatches in 
the middle of the spacer eliminate phage interference. Locations and identity of mismatches are 
shown in red. (n=3 biological replicates. ***, p < 0.001 compared to pACYC184 by t-test. Bars 
represent mean ± s.e.m). (C) Schematic showing the position and identity of single mismatches 
(red) in the crRNA spacer (top). Denaturing gel showing cleavage of ssRNA 1 guided by 
crRNAs with single mismatches in the spacer after 3 hours of incubation (bottom). Reported 
band lengths are matched from RNA sequencing. (D) Schematic showing the position and 
identity of pairs of mismatches (red) in the crRNA spacer (top). Denaturing gel showing 
cleavage of ssRNA 1 guided by crRNAs with pairs of mismatches in the spacer after 3 hours of 
incubation (bottom). Reported band lengths are matched from RNA sequencing. 
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Figure S20 
 
Fig. S20: MS2 restriction assay testing the effect of single and double mismatches on 
LshC2c2 activity.  
pLshC2c2 with protospacer 41 was modified to have a series of single mismatches and 
consecutive double mismatches as shown. Images from plaque assay testing these mismatched 
spacers reveals reduced plaque formation for the single-mismatch spacers on-par with the fully 
complementary spacer. The double mismatch spacers show increased plaque formation for a 
seed region in the middle of spacer sequence. Phage dilutions were spotted on bacteria plates at 
decreasing numbers of plaque forming units (PFU). Spacer targets are shown above images; 
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biological replicates are labeled BR1, BR2, or BR3. Non-targeting control is the native LshC2c2 
locus.   
	 37 
Figure S21 
 
Fig. S21. The effect of triple mismatches on LshC2c2-crRNA cleavage activity.  
(A) Schematic showing the position and identity of non-consecutive triple mismatches (red) in 
the crRNA spacer (top). Denaturing gel depicting LshC2c2 cleavage activity with crRNAs 
bearing triple non-consecutive mismatches between the spacer and ssRNA target region after 3 
hours of incubation (bottom). Reported band lengths are matched from RNA sequencing.  (B) 
Schematic showing the position and identity of consecutive triple mismatches (red) in the crRNA 
spacer (top). Denaturing gel depicting LshC2c2 cleavage activity with crRNAs bearing triple 
consecutive mismatches between the spacer and ssRNA target region after 3 hours of incubation 
(bottom). Reported band lengths are matched from RNA sequencing. 
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Figure S22 
 
Fig. S22: HEPN mutant LshC2c2 are tested for RFP mRNA targeting activity.  
The pLshC2c2 vector with protospacer 36 was modified to have the single HEPN mutants 
R597A and R1278A (one in each of the HEPN domains). These mutations resulted in little 
detectable RFP knockdown as measured by flow cytometry on the E. coli. (n=3 biological 
replicates. ***, p < 0.001 compared to wtLshC2c2 by t-test. Bars represent mean ± s.e.m) 
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Figure S23 
 
Fig. S23: Biochemical characterization of the collateral cleavage effect.  
(A) LshCc2 is incubated for 3 hours with a crRNA targeting protospacer 14 with and without 
unlabeled ssRNA target 1 (contains protospacer 14). When LshC2c2 is in the presence of target 
1, significant cleavage activity is observed for 5’ fluorescently labeled non-complementary 
targets 6-9. (B) HEPN mutant collateral activity is compared to WT C2c2. The proteins are 
incubated for 3 hours with crRNA complementary to protospacer 14 and with and without 
unlabeled homopolymer targets 2 or 3 (both containing protospacer 14). The collateral effect is 
no longer observed with the HEPN mutant proteins on the 3’ fluorescently labeled non-
complementary target 8.   
A B
Figure S15
collateral
RNA 6 7 8 9 6 7 8 9
1targetedssRNA 1 1 1 – – – –
+LshC2c2 + + + + + + +
+crRNA + + + + + + +
uncleaved
cleaved
collateral
RNA 8 8 8 8 8 8 8 8 8
2targetedssRNA 3 – 2 3 – 2 3 –
WTLshC2c2 WT WT R5
97A
R5
97A
R5
97A
R1
278
A
R1
278
A
R1
278
A
+crRNA + + + + + + ++
uncleaved
cleaved
	 40 
Figure S24 
 
 
Fig. S24. In vivo collateral effect reveals a 3’ H PFS with a PFS screen in a transcribed 
region.   
(A) Schematic for a transcribed and non-transcribed PFS screen. (B) 3’ PFS motif for a PFS 
screen designed in a transcribed plasmid region. (C) No PFS is observed for a PFS screen in a 
non-transcribed region.  
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Table S1. Number of top enriched crRNA sequences in all conditions of the MS2 screen.  
 
Condition # of targeting crRNAs with log2 normalized crRNA count 
> 1.25 (normalized to no phage condition) 
Phage 10-1 dilution replicate 1 617 
Phage 10-1 dilution replicate 2 630 
Phage 10-1 dilution replicate 3 703 
Phage 10-3 dilution replicate 1 508 
Phage 10-3 dilution replicate 2 524 
Phage 10-3 dilution replicate 3 436 
Phage 10-5 dilution replicate 1 452 
Phage 10-5 dilution replicate 2 515 
Phage 10-5 dilution replicate 3 367 
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Table S2. crRNA sequences used for in vitro experiments.  
 
Name Sequence 
1st 
Fig. 
crRNA 14 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU 2B 
crRNA 15 CCACCCCAAUAUCGAAGGGGACUAAAACUUUCUAGAGGAUCCCCGGGUACCGAGCU 2D 
crRNA 16 CCACCCCAAUAUCGAAGGGGACUAAAACAGUAAUCCAUAUUUCUAGAGGAUCCCCG 2D 
crRNA 17 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU 2D 
crRNA 18 CCACCCCAAUAUCGAAGGGGACUAAAACCAUGCCUGCAGGUCGAGUAGAUUGCUGU 2D 
crRNA 19 
CCACCCCAAUsAUCGAAGGGGACUAAAACGCAUGCCUGCAGGUCGAGUAGAUUGCU
G 2D 
crRNA 20 CCACCCCAAUAUCGAAGGGGACUAAAACAAGCUUGCAUGCCUGCAGGUCGAGUAGA 2D 
crRNA 21 CCACCCCAAUAUCGAAGGGGACUAAAACCGCCAAGCUUGCAUGCCUGCAGGUCGAG 2D 
crRNA 22 CCACCCCAAUAUCGAAGGGGACUAAAACGAUUACGCCAAGCUUGCAUGCCUGCAGG 2D 
crRNA 23 CCACCCCAAUAUCGAAGGGGACUAAAACUGAUUACGCCAAGCUUGCAUGCCUGCAG 2D 
crRNA 24 CCACCCCAAUAUCGAAGGGGACUAAAACAUGACCAUGAUUACGCCAAGCUUGCAUG 2D 
crRNA 25 CCACCCCAAUAUCGAAGGGGACUAAAACUAUGACCAUGAUUACGCCAAGCUUGCAU 2D 
crRNA 26 CCACCCCAAUAUCGAAGGGGACUAAAACAGCUAUGACCAUGAUUACGCCAAGCUUG 2D 
crRNA 27 CCACCCCAAUAUCGAAGGGGACUAAAACGAAACAGCUAUGACCAUGAUUACGCCAA 2D 
crRNA 28 CCACCCCAAUAUCGAAGGGGACUAAAACACAGGAAACAGCUAUGACCAUGAUUACG 2D 
crRNA 29 CCACCCCAAUAUCGAAGGGGACUAAAACAACACAGGAAACAGCUAUGACCAUGAUU 2D 
crRNA 30 CCACCCCAAUAUCGAAGGGGACUAAAACAAACACAGGAAACAGCUAUGACCAUGAU 2D 
crRNA 31 CCACCCCAAUAUCGAAGGGGACUAAAACAUAAACACAGGAAACAGCUAUGACCAUG 2D 
crRNA 32 CCACCCCAAUAUCGAAGGGGACUAAAACGGAUAAACACAGGAAACAGCUAUGACCA 2D 
crRNA 33 CCACCCCAAUAUCGAAGGGGACUAAAACAGCGGAUAAACACAGGAAACAGCUAUGA 2D 
crRNA 34 CCACCCCAAUAUCGAAGGGGACUAAAACGAGCGGAUAAACACAGGAAACAGCUAUG 2D 
Lsh_crRNA_DR
_28 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S16B 
Lsh_crRNA_DR
_26 ACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S16B 
Lsh_crRNA_DR
_24 CCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S16B 
Lsh_crRNA_DR
_22 CAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S16B 
Lsh_crRNA_DR
_20 AUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S16B 
Lsh_crRNA_DR
_19 UAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S16B 
Lsh_crRNA_DR
_18 AUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S16B 
Lsh_crRNA_24 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAU S16A 
Lsh_crRNA_23 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAA S16A 
Lsh_crRNA_22 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUA S16A 
Lsh_crRNA_21 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGU S16A 
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Lsh_crRNA_20 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAG S16A 
Lsh_crRNA_19 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAA S16A 
Lsh_crRNA_18 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCA S16A 
Lsh_crRNA_17 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACC S16A 
Lsh_crRNA_16 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUAC S16A 
Lsh_crRNA_12 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUU S16A 
Lsh_stem_1 CCACCCGAAUAUCGAACGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S17A 
Lsh_stem_2 CCACCGCAAUAUCGAAGCGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S17A 
Lsh_stem_3 CCACGCCAAUAUCGAAGGCGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S17A 
Lsh_stem_4 CCAGCCCAAUAUCGAAGGGCACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S17A 
Lsh_stem_5 
CCAGGGGGAAUAUCGAACCCCACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCA
U S17A 
Lsh_stem_6 
CCACCACCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCA
U S17A 
Lsh_stem_7 CCAACCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S17A 
Lsh_stem_8 CCACCCAAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S17A 
Lsh_stem_9 
CCACCCCCAAUAUCGAAGGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCC
AU S17A 
Lsh_loop_1 CCACCCCAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S17B 
Lsh_loop_2 CCACCCCAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S17B 
Lsh_loop_3 CCACCCCAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S17B 
Lsh_loop_4 
CCACCCCAAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCA
U S17B 
Lsh_loop_5 
CCACCCCAAAAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUC
CAU S17B 
Lsh_loop_6 
CCACCCCAAAAAAAAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGU
AAUCCAU S17B 
Lsh_loop_7 CCACCCCGAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S17B 
Lsh_loop_8 CCACCCCAAAAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S17B 
Lsh_loop_9 CCACCCCAAUAUCCAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU S17B 
Lsh_crRNA_fl
ip_8 
CCACCCCAAUAUCGAAGGGGUCUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU 
S18 
Lsh_crRNA_fl
ip_7 
CCACCCCAAUAUCGAAGGGGAGUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU 
S18 
Lsh_crRNA_fl
ip_6 
CCACCCCAAUAUCGAAGGGGACAAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU 
S18 
Lsh_crRNA_fl
ip_5 
CCACCCCAAUAUCGAAGGGGACUUAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU 
S18 
Lsh_crRNA_fl
ip_4 
CCACCCCAAUAUCGAAGGGGACUAUAACUAGAUUGCUGUUCUACCAAGUAAUCCAU 
S18 
Lsh_crRNA_fl
ip_3 
CCACCCCAAUAUCGAAGGGGACUAAUACUAGAUUGCUGUUCUACCAAGUAAUCCAU 
S18 
Lsh_crRNA_fl
ip_2 
CCACCCCAAUAUCGAAGGGGACUAAAUCUAGAUUGCUGUUCUACCAAGUAAUCCAU 
S18 
Lsh_crRNA_fl
ip_1 
CCACCCCAAUAUCGAAGGGGACUAAAAGUAGAUUGCUGUUCUACCAAGUAAUCCAU 
S18 
Lsh_crRNA_de
lete_8 
CCACCCCAAUAUCGAAGGGGCUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU 
S18 
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Lsh_crRNA_de
lete_7 
CCACCCCAAUAUCGAAGGGGAUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU 
S18 
Lsh_crRNA_de
lete_6 
CCACCCCAAUAUCGAAGGGGACAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU 
S18 
Lsh_crRNA_de
lete_5 
CCACCCCAAUAUCGAAGGGGACUAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU 
S18 
Lsh_crRNA_de
lete_4 
CCACCCCAAUAUCGAAGGGGACUAACUAGAUUGCUGUUCUACCAAGUAAUCCAU 
S18 
Lsh_crRNA_de
lete_3 
CCACCCCAAUAUCGAAGGGGACUACUAGAUUGCUGUUCUACCAAGUAAUCCAU 
S18 
Lsh_crRNA_de
lete_2 
CCACCCCAAUAUCGAAGGGGACUCUAGAUUGCUGUUCUACCAAGUAAUCCAU 
S18 
Lsh_crRNA_de
lete_1 
CCACCCCAAUAUCGAAGGGGACUAAAAUAGAUUGCUGUUCUACCAAGUAAUCCAU 
S18 
Lsh_single_m
ismatch_pos1 CCACCCCAAUAUCGAAGGGGACUAAAACAAGAUUGCUGUUCUACCAAGUAAUCCAU S19C 
Lsh_single_m
ismatch_pos5 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAAUGCUGUUCUACCAAGUAAUCCAU S19C 
Lsh_single_m
ismatch_pos9 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCAGUUCUACCAAGUAAUCCAU S19C 
Lsh_single_m
ismatch_pos1
3 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUGUACCAAGUAAUCCAU S19C 
Lsh_single_m
ismatch_pos1
7 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACGAAGUAAUCCAU S19C 
Lsh_single_m
ismatch_pos2
1 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGAAAUCCAU S19C 
Lsh_single_m
ismatch_pos2
5 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUGCAU S19C 
Lsh_single_m
ismatch_pos2
8 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAA S19C 
Lsh_double_m
ismatch_pos1 CCACCCCAAUAUCGAAGGGGACUAAAACAUGAUUGCUGUUCUACCAAGUAAUCCAU S19D 
Lsh_double_m
ismatch_pos6 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUACCUGUUCUACCAAGUAAUCCAU S19D 
Lsh_double_m
ismatch_pos1
1 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGAACUACCAAGUAAUCCAU S19D 
Lsh_double_m
ismatch_pos1
6 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUAGGAAGUAAUCCAU S19D 
Lsh_double_m
ismatch_pos2
1 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGAUAUCCAU S19D 
Lsh_double_m
ismatch_pos2
6 CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCGUU S19D 
Lsh_crRNA_MM
_2_1_5 
CCACCCCAAUAUCGAAGGGGACUAAAACAAGAAUGCUGUUCUACCAAGUAAUCCAU 
S21A 
Lsh_crRNA_MM
_2_1_9 
CCACCCCAAUAUCGAAGGGGACUAAAACAAGAUUGCAGUUCUACCAAGUAAUCCAU 
S21A 
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Lsh_crRNA_MM
_2_1_13 
CCACCCCAAUAUCGAAGGGGACUAAAACAAGAUUGCUGUUGUACCAAGUAAUCCAU 
S21A 
Lsh_crRNA_MM
_2_5_9 
CCACCCCAAUAUCGAAGGGGACUAAAACUAGAAUGCAGUUCUACCAAGUAAUCCAU 
S21A 
Lsh_crRNA_MM
_2_5_13 
CCACCCCAAUAUCGAAGGGGACUAAAACUAGAAUGCUGUUGUACCAAGUAAUCCAU 
S21A 
Lsh_crRNA_MM
_2_5_17 
CCACCCCAAUAUCGAAGGGGACUAAAACUAGAAUGCUGUUCUACGAAGUAAUCCAU 
S21A 
Lsh_crRNA_MM
_2_9_13 
CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCAGUUGUACCAAGUAAUCCAU 
S21A 
Lsh_crRNA_MM
_2_9_17 
CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCAGUUCUACGAAGUAAUCCAU 
S21A 
Lsh_crRNA_MM
_2_9_21 
CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCAGUUCUACCAAGAAAUCCAU 
S21A 
Lsh_crRNA_MM
_2_13_17 
CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUGUACGAAGUAAUCCAU 
S21A 
Lsh_crRNA_MM
_2_13_21 
CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUGUACCAAGAAAUCCAU 
S21A 
Lsh_crRNA_MM
_2_13_25 
CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUGUACCAAGUAAUGCAU 
S21A 
Lsh_crRNA_MM
_3_1 
CCACCCCAAUAUCGAAGGGGACUAAAACAUCAUUGCUGUUCUACCAAGUAAUCCAU 
S21B 
Lsh_crRNA_MM
_3_6 
CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUACGUGUUCUACCAAGUAAUCCAU 
S21B 
Lsh_crRNA_MM
_3_11 
CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGAAGUACCAAGUAAUCCAU 
S21B 
Lsh_crRNA_MM
_3_16 
CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUAGGUAGUAAUCCAU 
S21B 
Lsh_crRNA_MM
_3_21 
CCACCCCAAUAUCGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGAUUUCCAU 
S21B 		 	
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Table S3. ssRNA targets used in this study. 	
Name Target 
1st 
Fig.  
ssRNA 1 (C 
PFS) 
GGCCAGUGAAUUCGAGCUCGGUACCCGGGGAUCCUCUAGAAAUAUGGAUUACUUGG
UAGAACAGCAAUCUACUCGACCUGCAGGCAUGCAAGCUUGGCGUAAUCAUGGUCAU
AGCUGUUUCCUGUGUUUAUCCGCUCACAAUUCCACACAACAUACGAGCCGGAAGCA
UAAAG 2B 
ssRNA 2 
AAUAUGGAUUACUUGGUAGAACAGCAAUCUACAAAAAAAAAAAAAAAAAAAGAAAA
AAAAAAAAAAAAAAAGAAAAAAAAAAAAAAAAAAAGAAAAAAAAAAAAAAAAAAAG
AAAAAAAAAAAAAAAAAAAGAAAAAAAAAAAAAAAAAAAG S12 
ssRNA 3 
AAUAUGGAUUACUUGGUAGAACAGCAAUCUACUUUUUUUUUUUUUUUUUUUCUUUU
UUUUUUUUUUUUUUUCUUUUUUUUUUUUUUUUUUUCUUUUUUUUUUUUUUUUUUUC
UUUUUUUUUUUUUUUUUUUCUUUUUUUUUUUUUUUUUUUC S12 
ssRNA 4 
GGGUAGGUGUUCCACAGGGUAGCCAGCAGCAUCCUGCGAUGCAAAUAUGGAUUACU
UGGUAGAACAGCAAUCUAAUCCGGAACAUAAUGGUGCAGGGCGCUGACUUCCGCGU
UUCCAGACUUUACGAAACACGGAAACCGAAGACCAUUCAUGUUGUUGCUGCCGGAA
GCAUAAAG 3A 
ssRNA 5 
GGGCCCCUCCGUUCGCGUUUACGCGGACGGUGAGACUGAAGAUAAUAUGGAUUACU
UGGUAGAACAGCAAUCUAAACUCAUUCUCUUUAAAAUAUCGUUCGAACUGGACUCC
CGGUCGUUUUAACUCGACUGGGGCCAAAACGAAACAGUGGCACUACCCCGCCGGAA
GCAUAAAG 3A 
ssRNA 1 (G 
PFS) 
GGCCAGUGAAUUCGAGCUCGGUACCCGGGGAUCCUCUAGAAAUAUGGAUUACUUGG
UAGAACAGCAAUCUAGUCGACCUGCAGGCAUGCAAGCUUGGCGUAAUCAUGGUCAU
AGCUGUUUCCUGUGUUUAUCCGCUCACAAUUCCACACAACAUACGAGCCGGAAGCA
UAAAG 2C 
ssRNA 1 (A 
PFS) 
GGCCAGUGAAUUCGAGCUCGGUACCCGGGGAUCCUCUAGAAAUAUGGAUUACUUGG
UAGAACAGCAAUCUAAUCGACCUGCAGGCAUGCAAGCUUGGCGUAAUCAUGGUCAU
AGCUGUUUCCUGUGUUUAUCCGCUCACAAUUCCACACAACAUACGAGCCGGAAGCA
UAAAG 2C 
ssRNA 1 (U 
PFS) 
GGCCAGUGAAUUCGAGCUCGGUACCCGGGGAUCCUCUAGAAAUAUGGAUUACUUGG
UAGAACAGCAAUCUAUUCGACCUGCAGGCAUGCAAGCUUGGCGUAAUCAUGGUCAU
AGCUGUUUCCUGUGUUUAUCCGCUCACAAUUCCACACAACAUACGAGCCGGAAGCA
UAAAG 2C 
ssRNA 6 
ACCGAUCGUCGUUGUUUGGGCAAUGCACGUUCUCCAACGGUGCUCCUAUGGGGCAC
AAGUUGCAGGAUGCAGCGCCUUACAAGAAGUUCGCUGAACAAGCAACCGUUACCCC
CCGCGCUCUGAGAGCGGCUCUAUUGGUCCGAGACCAAUGUGCGCCGUGGAUCAGAC
ACGCGGU 6B 
ssRNA 7 
ACUGUUGGUGGUGUAGAGCUUCCUGUAGCCGCAUGGCGUUCGUACUUAAAUAUGGA
ACUAACCAUUCCAAUUUUCGCUACGAAUUCCGACUGCGAGCUUAUUGUUAAGGCAA
UGCAAGGUCUCCUAAAAGAUGGAAACCCGAUUCCCUCAGCAAUCGCAGCAAACUCC
GGCAUCU 6B 
ssRNA 8 
GGUAACAUGCUCGAGGGCCUUACGGCCCCCGUGGGAUGCUCCUACAUGUCAGGAAC
AGUUACUGACGUAAUAACGGGUGAGUCCAUCAUAAGCGUUGACGCUCCCUACGGGU
GGACUGUGGAGAGACAGGGCACUGCUAAGGCCCAAAUCUCAGCCAUGCAUCGAGGG
GUACAAU 6B 
ssRNA 9 
UUCGUAAAACGUUCGUGUCCGGGCUCUUUCGCGAGAGCUGCGGCGCGCACUUUUAC
CGUGGUGUCGAUGUCAAACCGUUUUACAUCAAGAAACCUGUUGACAAUCUCUUCGC
CCUGAUGCUGAUAUUAAAUCGGCUACGGGGUUGGGGAGUUGUCGGAGGUAUGUCAG
AUCCACG 6B 
ssRNA 10 
AUAGGCCAGUGAAUUCGAGCUCGAAUAUGGAUUACUUGGUAGAACAGCAAUCUACG
CCGGAAGCAUAAAG 4D 
ssRNA 10(rc) 
CUUUAUGCUUCCGGCGUAGAUUGCUGUUCUACCAAGUAAUCCAUAUUCGAGCUCGA
AUUCACUGGCCUAU 4D 
ssDNA target ctttatgcttccggctcgtatgttgtgtggaattgtgagcggataaacacaggaaa S10D 
	 47 
cagctatgaccatgattacgccaagcttgcatgcctgcaggtcgagaatatggatt
acttggtagaacagcaatctatctagaggatccccgggtaccgagctcgaattcac
tggccccctatagtgagtcgtattaatttc 
modified 
ssRNA 1 U40A 
GGGGGCCAGUGAAUUCGAGCUCGGUACCCGGGGAUCCUCAAGAAAUAUGGAUUACU
UGGUAGAACAGCAAUCUACUCGACCUGCAGGCAUGCAAGCUUGGCGUAAUCAUGGU
CAUAGCUGUUUCCUGUGUUUAUCCGCUCACAAUUCCACACAACAUACGAGCCGGAA
GCAUAAAG 3D 
modified 
ssRNA 1 U73A 
GGGGGCCAGUGAAUUCGAGCUCGGUACCCGGGGAUCCUCUAGAAAUAUGGAUUACU
UGGUAGAACAGCAAUCAACUCGACCUGCAGGCAUGCAAGCUUGGCGUAAUCAUGGU
CAUAGCUGUUUCCUGUGUUUAUCCGCUCACAAUUCCACACAACAUACGAGCCGGAA
GCAUAAAG 3D 
modified 
ssRNA 1 U90A 
GGGGGCCAGUGAAUUCGAGCUCGGUACCCGGGGAUCCUCUAGAAAUAUGGAUUACU
UGGUAGAACAGCAAUCUACUCGACCUGCAGGCAAGCAAGCUUGGCGUAAUCAUGGU
CAUAGCUGUUUCCUGUGUUUAUCCGCUCACAAUUCCACACAACAUACGAGCCGGAA
GCAUAAAG 3D 
modified 
ssRNA 1 U103A 
GGGGGCCAGUGAAUUCGAGCUCGGUACCCGGGGAUCCUCUAGAAAUAUGGAUUACU
UGGUAGAACAGCAAUCUACUCGACCUGCAGGCAUGCAAGCUUGGCGAAAUCAUGGU
CAUAGCUGUUUCCUGUGUUUAUCCGCUCACAAUUCCACACAACAUACGAGCCGGAA
GCAUAAAG 3D 
modified 
ssRNA 4 poly 
U  
GGGUAGGUGUUCCACAGGGUAGCCAGCAGCAUCCUGCGAUGCAAAUAUGGAUUACU
UGGUAGAACAGCAAUCUAAUCCGGAACAUAAUGGUGCAGGGCGCUGACUUCCGCGU
UUGUUUUAAAUCAAACACGGAAACCGAAGACCAUUCAUGUUGUUGCUGCCGGAAGC
AUAAAG S12G 
modified 
ssRNA 4 poly 
C  
GGGUAGGUGUUCCACAGGGUAGCCAGCAGCAUCCUGCGAUGCAAAUAUGGAUUACU
UGGUAGAACAGCAAUCUAAUCCGGAACAUAAUGGUGCAGGGCGCUGACUUCCGCGU
UUGCCCCAAACCAAACACGGAAACCGAAGACCAUUCAUGUUGUUGCUGCCGGAAGC
AUAAAG S12G 
modified 
ssRNA 4 poly 
G  
GGGUAGGUGUUCCACAGGGUAGCCAGCAGCAUCCUGCGAUGCAAAUAUGGAUUACU
UGGUAGAACAGCAAUCUAAUCCGGAACAUAAUGGUGCAGGGCGCUGACUUCCGCGU
UUGGGGGAAAGCAAACACGGAAACCGAAGACCAUUCAUGUUGUUGCUGCCGGAAGC
AUAAAG S12G 
modified 
ssRNA 4 poly 
A  
GGGUAGGUGUUCCACAGGGUAGCCAGCAGCAUCCUGCGAUGCAAAUAUGGAUUACU
UGGUAGAACAGCAAUCUAAUCCGGAACAUAAUGGUGCAGGGCGCUGACUUCCGCGU
UUGAAAAAAAACAAACACGGAAACCGAAGACCAUUCAUGUUGUUGCUGCCGGAAGC
AUAAAG S12G 	 	
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Table S4. Spacers used for in vivo experiments.  
 
Name Sequence  
1st 
Fig. 
spacer 1 GAAGUUUGCAGCUGGAUACGACAGACGG 1D 
spacer 2 UGUCUGGAAGUUUGCAGCUGGAUACGAC 1D 
spacer 3 AGCUGGAUACGACAGACGGCCAUCUAAC 1D 
spacer 4 UACGUCGCGAUAUGUUGCACGUUGUCUG 1D 
spacer 5 UACGGACGACCUUCACCUUCACCUUCGAUUU 5A 
spacer 6 UCGUACGGACGACCUUCACCUUCACCUUCGA 5A 
spacer 7 CGGUCUGGGUACCUUCGUACGGACGACCUUC 5A 
spacer 8 GCGGUCUGGGUACCUUCGUACGGACGACCUU 5A 
spacer 9 AGCGGUCUGGGUACCUUCGUACGGACGACCU 5A 
spacer 10 AGUUCAUAACACGUUCCCAUUUGAAACCUUC 5A 
spacer 11 UUAACUUUGUAGAUGAACUCACCGUCUUGCA 5A 
spacer 12 UUUAACUUUGUAGAUGAACUCACCGUCUUGC 5A 
spacer 13 GUUUAACUUUGUAGAUGAACUCACCGUCUUG 5A 
spacer 35 AAGUUUGCAGCUGGAUACGACAGACGGC 4B 
spacer 36 ACAGGAUGUCCCAAGCGAACGGCAGCGG S22 
spacer 37 GCUUGUUCAGCGAACUUCUUGUAAGGCG S4A 
spacer 38 UAAGCUCGCAGUCGGAAUUCGUAGCGAA S4A 
spacer 39 CGUCAACGCUUAUGAUGGACUCACCCGU S4A 
spacer 40 UCAACAGGUUUCUUGAUGUAAAACGGUU S4A 
spacer 41 AAGUUUGCAGCUGGAUACGACAGACGGC S5 
spacer 42 UUUGCAGCUGGAUACGACAGACGGCCAU S5 
spacer 43 CAGCUGGAUACGACAGACGGCCAUCUAA S5 
spacer 44 GUUGUCUGGAAGUUUGCAGCUGGAUACG S5 
spacer 45 GCGAUAUGUUGCACGUUGUCUGGAAGUU S5 
spacer 46 ACGUUGUCUGGAAGUUUGCAGCUGGAUA S5 
spacer 47 AUGUUGCACGUUGUCUGGAAGUUUGCAG S5 
spacer 48 UGCAGCUGGAUACGACAGACGGCCAUCU S5 
spacer 49 CUGGAAGUUUGCAGCUGGAUACGACAGA S5 
spacer 50 AGUUUGCAGCUGGAUACGACAGACGGCC S5 
spacer 51 GCUGGAUACGACAGACGGCCAUCUAACU S5 
spacer 52 GUUUGCAGCUGGAUACGACAGACGGCCA S5 
spacer_41_sin
gle_mismatch_
pos1 UAGUUUGCAGCUGGAUACGACAGACGGC S19A 
	 49 
spacer_41_sin
gle_mismatch_
pos5 AAGUAUGCAGCUGGAUACGACAGACGGC S19A 
spacer_41_sin
gle_mismatch_
pos9 AAGUUUGCUGCUGGAUACGACAGACGGC S19A 
spacer_41_sin
gle_mismatch_
pos13 AAGUUUGCAGCUCGAUACGACAGACGGC S19A 
spacer_41_sin
gle_mismatch_
pos17 AAGUUUGCAGCUGGAUUCGACAGACGGC S19A 
spacer_41_sin
gle_mismatch_
pos21 AAGUUUGCAGCUGGAUACGAGAGACGGC S19A 
spacer_41_sin
gle_mismatch_
pos25 AAGUUUGCAGCUGGAUACGACAGAGGGC S19A 
spacer_41_dou
ble_mismatch_
pos1 UUGUUUGCAGCUGGAUACGACAGACGGC S19B 
spacer_41_dou
ble_mismatch_
pos6 AAGUUACCAGCUGGAUACGACAGACGGC S19B 
spacer_41_dou
ble_mismatch_
pos11 AAGUUUGCAGGAGGAUACGACAGACGGC S19B 
spacer_41_dou
ble_mismatch_
pos16 AAGUUUGCAGCUGGAAUCGACAGACGGC S19B 
spacer_41_dou
ble_mismatch_
pos21 AAGUUUGCAGCUGGAUACGAGUGACGGC S19B 
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Table S5. Plasmid maps for experiments in this study.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasmid Name Link to plasmid map in Benchling 
huLshC2c2-MBP for bacterial expression https://benchling.com/s/Jl1pExm8/edit 
LshC2c2 locus into pACYC184 https://benchling.com/s/E8LxbHUl/edit 
LshC2c2 locus into pACYC184 with BsaI sites 
for spacer cloning 
https://benchling.com/s/nJshaXmE/edit 
PFS library in Beta-lactamase gene Screening 
Plasmid 
https://benchling.com/s/lPJ1cCwR/edit 
transcribed PFS library https://benchling.com/s/yE6mFoYb/edit 
non-transcribed PFS library https://benchling.com/s/JoOerzaE/edit 
pRFP with constitutive expression https://benchling.com/s/JJrHLrVZ/edit 
pBR322 with tetR-inducible RFP https://benchling.com/s/JmviNU13/edit 
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